K S Drug Research Laboratoroes Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 1.77 M
- Company Age 40 Year, 3 Months
- Last Filing with ROC 31 Mar 2009
- Satisfied Charges ₹ 0.50 M
About K S Drug Research Laboratoroes
Company Details
-
Location
Thrissur, Kerala, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24231KL1984PLC004078
-
Company No.
004078
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
16 Nov 1984
-
Date of AGM
30 Sep 2009
-
Date of Balance Sheet
31 Mar 2009
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at K S Drug Research Laboratoroes?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Parambikattil Krishnan
![]() |
Managing Director | 16-Nov-1984 | Current |
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Mundeli Chandran
![]() |
Director | 23-Jun-2009 | Current |
Lakshmi Krishnan
![]() |
Director | 15-Feb-1992 | Current |
Balasubramanian Kuttan
![]() |
Director | 02-Feb-2009 | Current |
Financial Performance of K S Drug Research Laboratoroes.
Enhance accessibility to K S Drug Research Laboratoroes's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
![Graph illustrating revenue growth over time](/Images/financial/revenue-growth.webp)
![Graph showing profit and loss trends over time](/Images/financial/profit-loss.webp)
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of K S Drug Research Laboratoroes?
Unlock access to K S Drug Research Laboratoroes's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
![Shareholding Indicator graph](/Images/tcc-login/Shareholding-Indiacator-1200.webp)
Charges (Loans)
₹0
₹0.50 M
Charges Breakdown by Lending Institutions
- State Bank Of Travancore : 0.05 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
06 Dec 1996 | State Bank Of Travancore | ₹0.50 M | Satisfied |
How Many Employees Work at K S Drug Research Laboratoroes?
Unlock and access historical data on people associated with K S Drug Research Laboratoroes, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
![Graph showing employee growth trends](/Images/tcc-login/Employee-Graph.webp)
Deals i
![Graph showing company valuation over time](/Images/tcc-login/Valuation-Graph-small.webp)
Gain comprehensive insights into the Deals and Valuation data of K S Drug Research Laboratoroes, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped K S Drug Research Laboratoroes's trajectory.
Rating
![Graph displaying rating trends over time](/Images/tcc-login/Rating-Graph-small.webp)
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
![Alert Indicator](/Images/tcc-login/Alert-Indicator-small.webp)
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.